Johnson & Johnson's Strategy for Cancer Biotech Deals Examined

An article examines Johnson & Johnson's successful strategy in securing cancer biotech deals at favorable prices. It questions whether the pharmaceutical giant can maintain its innovative edge in the competitive biotechnology landscape.